Soufflé Therapeutics
PrivateLast Round
Series B
Oct 13, 2026
Total Funding Raised
$335M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Soufflé Therapeutics is a biotechnology company that develops cell-specific small interfering RNA (siRNA) medicines for the treatment of genetic, cardiovascular, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Soufflé Therapeutics Comparables
Compare Soufflé Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| City Therapeutics | 89% | |
| Sanegene Bio | 87% | |
| ADARx Pharmaceuticals | 84% |
Soufflé Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 13, 2026 | ||||
| Series A | Oct 7, 2025 |
Key People
Founding team and executive leadership
Soufflé Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Breyer Capital | Series A, Series B |
| Janus Henderson Group | Series A, Series B |
| Balyasny Asset Management L.P. | Series B |
| Temasek | Series A, Series B |
| TCG Crossover | Series B |
| BB Biotech | Series B |
| ARCH Venture Partners | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 13, 2026
$135M round led by Juvia Group.
- Oct 12, 2026
Open roles increased to 35, representing 38% of headcount.
Recent news
Latest coverage and updates
- receives_financingOct 13, 2026
Soufflé Therapeutics, Inc. receives an oversubscribed $135M Series B financing led by Juvia Group, with participation from institutional investors, to advance clinical programs and pipeline development in Massachusetts on Oct 13th '26.
Soufflé Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Soufflé Therapeutics's valuation, stock price, and market status.
Is Soufflé Therapeutics a public or private company?
Soufflé Therapeutics is a private company.
What is the current stock price of Soufflé Therapeutics?
Soufflé Therapeutics is a private company, so its shares have no public market price. Caplight tracks Soufflé Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Soufflé Therapeutics worth (valuation)?
Valuation information for Soufflé Therapeutics is not publicly available.
Can I buy Soufflé Therapeutics stock?
Soufflé Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Soufflé Therapeutics's last funding round?
Soufflé Therapeutics's most recent funding round was Series B on October 13, 2026.
Who are the main investors in Soufflé Therapeutics?
Key investors in Soufflé Therapeutics include Juvia Group, Bessemer Venture Partners.
Will Soufflé Therapeutics IPO soon?
No public IPO plans have been announced for Soufflé Therapeutics.
How can I track Soufflé Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Soufflé Therapeutics's shares on secondary markets.